Comparative Pharmacology
Head-to-head clinical analysis: CONTEPO versus STRIANT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONTEPO versus STRIANT.
CONTEPO vs STRIANT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the enzyme UDP-N-acetylglucosamine-3-enolpyruvyltransferase (MurA), which catalyzes the formation of N-acetylmuramic acid, a critical component of the bacterial cell wall. It is bactericidal against a broad range of Gram-positive and Gram-negative bacteria.
Testosterone replacement therapy. Testosterone is an androgen that binds to and activates androgen receptors, leading to increased protein synthesis, bone mineralization, and erythropoiesis. It also virilizes and promotes secondary sexual characteristics.
CONTEPO (fosfomycin tromethamine for injection) is typically administered as 4 grams intravenously every 8 hours.
30 mg buccal system applied to the gum above the incisor tooth twice daily, once in the morning and once in the evening.
None Documented
None Documented
6.9 hours (terminal elimination half-life); prolonged in renal impairment (up to 24 hours in severe impairment), necessitating dose adjustment for CrCl <50 mL/min.
Terminal half-life approximately 10-20 minutes after IV administration; buccal administration yields an effective half-life of 1-2 hours due to prolonged absorption
Primarily renal (approximately 80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for <15%.
Urinary (90% as glucuronide and sulfate conjugates, 6% as unchanged drug); fecal (6%)
Category C
Category C
Testosterone Replacement
Testosterone Replacement